Skip to main content
. 2012 Jun;24(2):130–137. doi: 10.1007/s11670-012-0130-y

Table 2. Differences between high and low expression of TGF-β1 among several clinical data.

    Clinicopathological characteristic TGF-β1low (n=50) TGF-β1high (n=29)     P
    Age (year)     53.96±11.03     54.86±11.62     0.732
    Histological grade     I     4 (8.0)     5 (17.2)     0.352
    [n (%) ]     II     18 (36.0)          12 (41.4)
    III     28 (56.0)     12 (41.4)
    FIGO stage     FIGO I     7 (14.0)     4 (13.8)     0.916
    [n (%) ]     FIGO II     10 (20.0)     4 (13.8)
    FIGO III     30 (60.0)     19 (65.5)
    FIGO IV     3 (6.0)     2 (6.9)
    Residual tumor     0     21 (42.0)     8 (27.6)     0.256
    [n (%) ]     <2 cm     11 (22.0)     11 (37.9)
    >2 cm     18 (36.0)     10 (34.5)
    Lymphatic metastasis     Negative     21 (42.0)     12 (41.4)     0.840
    [n (%) ]     Positive     18 (36.0)     12 (41.4)
    Unclear     11 (22.0)     5 (17.2)
    Chemotherapy     Standard     39 (68.0)     24 (82.8)     0.450
    [n (%) ]     Nonstandard     11 (22.0)     5 (17.2)

The standard chemotherapy was defined as: at least 6 cycles of fist-line chemotherapy (cisplatin+taxol; carboplatin+taxol; or cisplatin+adriamycin+cyclophosphamide) after cytoreductive surgery.